Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

Company Overview

Santhera Pharmaceuticals Ltd is a Swiss-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases. Headquartered in Pratteln, Switzerland, the company focuses on addressing unmet medical needs by targeting mitochondrial dysfunction and inflammation pathways. Santhera holds global marketing rights for Raxone (idebenone), its lead product approved in Europe for the treatment of vision loss in Friedreich’s ataxia and under regulatory review in other jurisdictions.

In addition to Raxone, Santhera’s clinical pipeline features Puldysa (vamorolone), a novel steroid-like therapeutic under investigation for Duchenne muscular dystrophy. This candidate aims to retain the efficacy of corticosteroids while reducing associated side effects. The company is also advancing exploratory programs that target cardiopulmonary complications in rare disease populations, leveraging partnerships with academic institutions and patient advocacy organizations to accelerate research and broaden its precision medicine platform.

Operating from Switzerland with supporting offices in North America and Europe, Santhera manages regulatory submissions, clinical trials and potential commercial launches across multiple regions. The management team brings extensive experience in rare disease drug development, regulatory strategy and global market access, driving the company’s mission to deliver transformative treatments for patients with high unmet needs.

Key Stats

• Today's Range: $14.75 to $14.75
• 50-Day Range: $14.75 to $17.54
• 52-Week Range: $14.75 to $17.54
• Volume: N/A
• Average Volume: 241 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SPHDF Stock Analysis - Frequently Asked Questions

How have SPHDF shares performed this year?

Santhera Pharmaceuticals' stock was trading at $9.42 at the beginning of 2025. Since then, SPHDF shares have increased by 56.6% and is now trading at $14.75.

When did Santhera Pharmaceuticals' stock split?

Santhera Pharmaceuticals shares reverse split on Monday, July 3rd 2023.The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Santhera Pharmaceuticals?

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Next Earnings (Estimated): 9/10/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPHDF
• CIK: N/A
• Web: www.santhera.com
• Phone: (161) 906-8950
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A